Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062231 | 0.89 | CASP1 (0.33) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL1064925 | 0.88 | CACNA1G (0.33) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1063252 | 0.88 | P2RX3 (0.33) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1061639 | 0.86 | CACNA1G (0.36) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1062681 | 0.86 | CCNK (0.33) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1066983 | 0.86 | CACNA1G (0.32) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1083161 | 0.83 | CASP1 (0.33) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL1065244 | 0.83 | CASP1 (0.33) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL1061175 | 0.83 | CASP1 (0.33) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL1063371 | 0.82 | CACNA1G (0.36) | CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |